Global Autoimmune Disease Therapeutics Market: Analysis By Drug Class (Anti-inflammatory, Interferons, NSAIDs and Antihyperglycemics) By Indication (Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease, Type 1 Diabetes) By Region (North Am

Global Autoimmune Disease Therapeutics Market: Analysis By Drug Class (Anti-inflammatory, Interferons, NSAIDs and Antihyperglycemics) By Indication (Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease, Type 1 Diabetes) By Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America) Size & Trends with Impact of Covid-19 and Forecast up to 2025

Scope of the Report

The report provides an in depth analysis of the global autoimmune disease therapeutics market by value, by drug class, by indication, by region, etc. The report provides a regional analysis of the autoimmune disease therapeutics market, including the following regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The report also provides a detailed analysis of the COVID-19 impact on the autoimmune disease therapeutics market.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global autoimmune disease therapeutics market has also been forecasted till the period 2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global autoimmune disease therapeutics market is fragmented with many major market players operating worldwide. The key players of the autoimmune disease therapeutics market are Roche Holding AG, Pfizer Inc., Johnson & Johnson, and Abbott Laboratories are also profiled with their financial information and respective business strategies.

Country Coverage

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Company Coverage

Roche Holding AG
Pfizer Inc.
Johnson & Johnson
Abbott Laboratories

Executive Summary

An autoimmune disease is a condition in which the body’s immune system attacks and destroys healthy cells and tissues in the body by mistake. In other words, autoimmune disease arises when the immune system fails to distinguish between the body’s own cells and foreign cells. These diseases can affect any part of the body. Autoimmune disease therapeutics is a form of treatment to calm the overactive immune response, to limit tissue damage, and to reduce pain and inflammation. Treatment can also help in relieving symptoms like pain, swelling, and skin rashes.

There are a lot of therapeutic alternatives available, but no option has a perfect safety profile. Infact, while some treatments have been effective in treating certain autoimmune disorders, no treatment is effective for all autoimmune diseases.

The autoimmune disease therapeutics market can be segmented on the basis of drug class (Immunosuppressant’s, Anti-inflammatory Drug, Interferons, NSAIDs, Antihyperglycemics, and Others); indication (Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease, Type 1 Diabetes, Psoriasis, and Others); and distribution channel (Hospital & Clinics, Pharmacies, Drug Stores, Online Stores, and Others).

The global autoimmune disease therapeutics market has increased significantly during the past years and projections are made that the market would rise in the next few years. The autoimmune disease therapeutics market is expected to increase due to rapid urbanization, escalating healthcare spending, rising prevalence of autoimmune diseases, favorable government initiatives, etc. Yet the market faces some challenges such as high cost involved, lack of approved treatment for IPF (Idiopathic Pulmonary Fibrosis), etc.